Because aortic root dilatation and resulting dissection are the most life-threatening problems in patients with Marfan syndrome, research has focused on mitigating the risk for these complications. Whereas surgical replacement of the dilated aorta remains the most effective intervention, medical treatment aimed at reducing aortic root growth also contributes to improved outcome. β blockers are considered the gold standard for this purpose, with an effect most likely achieved by reducing aortic wall shear stress. 1 A major discovery in the research to unravel the underlying pathogenesis of this condition was the demonstration of the transforming growth factor β (TGF-β) pathway involvement. 2 This openedup perspectives for new treatment options through blockade of TGF-β, where angiotensin-II receptor blockers (ARBs) seemed an attractive option. The precise contribution of TGF-β has still not been fully elucidated. It has been shown that TGF-β has dual effects and should be regarded as a marker rather than a cause of pathology. 3 Nevertheless, the publication of the remarkable results, showing that losartan, an ARB, improved aortic growth in a mouse model of Marfan syndrome, had an impact in the Marfan syndrome community. 4 At least eight studies with losartan have been done. [5] [6] [7] [8] Albeit with variable study design and populations, these studies showed that the results achieved in animal models could not be replicated in humans, leading to further speculation about possible explanations.
One of the hypotheses was that the lower bioavailability (33%) and short half-life (2 h) 9 of losartan might provide insufficient protection. Therefore, irbesartan, an ARB with longer bioavailability (up to 80%) and half-life (up to 15 h), 9 could result in a better outcome. For this reason, the study by Michael Mullen and colleagues 10 in The Lancet is very interesting. This randomised placebo-controlled trial shows that the intake of irbesartan significantly reduced aortic root dilatation in patients with Marfan syndrome (mean aortic root growth 0·53 mm per year [95% CI 0·39 to 0·67] in the irbesartan group vs 0·74 mm per year [0·60 to 0·89] in the placebo group; difference -0·22 mm per year [-0·41 to -0·02]; p=0·030). This moderate effect was mainly achieved during the first year of treatment and was maintained throughout the 4 subsequent years. A parallel effect was observed on blood pressure, suggesting a possible association between lowering blood pressure and aortic growth. On the basis of these findings, previous conclusions are confirmed: the use of ARBs to inhibit aortic growth in patients with Marfan syndrome can certainly be considered.
Several recurring and unresolved questions in the design and interpretation of studies of ARBs have unfortunately not been clarified by this study either. First, many such studies are confronted with the issue of difficult patient recruitment. In the study by Mullen and colleagues, 10 not even half of the anticipated number of patients was achieved. This difficulty has to do with the rarity of the condition and with the difficulty of convincing patients to participate in research after the publication of preclinical trials.
Second, another limiting factor is the low hard event rate (aortic dissection and death), which forces all studies to rely on indirect outcome parameters, such as aortic root growth. Furthermore, an additional limitation of this study is the inclusion of both children and adults (192 patients with Marfan syndrome with a median age of 18 years [IQR 12-28]). Apart from somatic growth in half of the study population, which is difficult to account for, there is the problem of the measurement of the aorta itself and the calculation of the Z scores. Although aortic Z score values were used as a secondary outcome in this study, applying methods for Z score calculation based on data obtained in different age populations and using different echocardiographic methods is cumbersome. The authors sought to solve this difficulty by calculating the Z score according to the Devereux method 11 (developed for application in adult patients) while using the Pettersen reference 12 (developed for application in paediatric patients) as a sensitivity analysis.
A final consideration is that 108 (56%) patients in the cohort were taking β blockers. The authors tried to account for the confounding effect of β blockers through conventional stratified analysis, but the study was underpowered to perform meaningful subgroup evaluation (especially given the drop-out rate of 24% in the irbesartan group and 15% in the placebo group). Subsequently, evaluation of how the observed effect
